Related Experiment Video
Updated: May 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
The bootstrap in bioequivalence studies
Iris Pigeot1, Dieter Hauschke, Jun Shao
1Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Bremen, Germany. pigeot@bips.uni-bremen.de
Abstract:
In 1997, the U.S. Food and Drug Administration (FDA) suggested in its draft guidance the use of new concepts for assessing the bioequivalence of two drug formulations, namely, the concepts of population and individual bioequivalence. Aggregate moment-based and probability-based measures of bioequivalence were introduced to derive criteria in order to decide whether two formulations should be regarded as bioequivalent or not. The statistical decision may be made via a nonparametric bootstrap percentile interval. In this article, we review the history of population and individual bioequivalence with special focus on the role of the bootstrap in this context.
Related Concept Videos
Bioequivalence Data: Statistical Interpretation
Bioequivalence studies: Biowaivers
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence: Overview
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Equivalence: In Vitro and In Vivo Bioequivalence
